AVEO reports total revenue of $133.

Under the terms of the contract, AVEO received $125 million in up-front payments from Astellas. AVEO can be eligible to receive approximately $1.3 billion in potential milestones comprised of $575 million in scientific and regulatory milestones, including $90 million in connection with regulatory filings and advertising approval in THE UNITED STATES and Europe for tivozanib as a monotherapy in first-line renal cell carcinoma , in addition to more than $780 million in commercial milestones. As well as the ongoing Phase 3 TIVO-1 trial and Stage 1b combination research of tivozanib, AVEO and Astellas will jointly conduct and fund the accelerated expansion of tivozanib clinical development into extra solid tumor types beyond RCC prior to top-line TIVO-1 data.AGA Research Foundation's Corporate Roundtable, which engages clinical and corporate GI leaders in discussions regarding scientific advancements, policy, legislation and other issues and opportunities that impact the technology and practice of gastroenterology and hepatology. ‘Research and development of novel gadgets and technologies is crucial to advancing patient care,’ said Vafa Jamali, vice president and general manager, GI Solutions, Covidien. ‘We are pleased to expand our partnership with the AGA Institute and the AGA Analysis Foundation.